Shares of ROKIT Healthcare, an artificial intelligence (AI)-based organ regeneration platform corporation, surged early on the 18th. This was influenced by the news that a key technology patent related to cartilage regeneration had been registered with the Korean Intellectual Property Office.
As of 9:12 a.m. on the same day, ROKIT Healthcare's shares were trading at 160,010 won, up 16.27% (2,240 won) compared to the previous trading day on the Korea Securities Dealers Automated Quotations (KOSDAQ).
Earlier, ROKIT Healthcare officially announced that it had completed the registration of a key technology patent related to cartilage regeneration with the U.S. Patent and Trademark Office.
The U.S. patent that ROKIT Healthcare has registered is for a technology related to "ultra-personalized hyaline cartilage regeneration therapeutic composition." The company noted that this signifies the technological independence and global competitiveness of the AI-based cartilage regeneration platform developed by ROKIT Healthcare.